Program
TQH2929
A development code. Also written as “TQH2929 Injections”, “TQH2929 Injection” and “TQH2929 injection”.
In Sino Biopharmaceutical's pipeline, IL-36R抑制剂
. Its studies are mostly in Psoriasis, led by Sino Biopharmaceutical.
Furthest: phase 2, since Dec 15, 20253 company-led studies, 1 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sino Biopharmaceutical | 31 open or running | phase 2since Dec 15, 2025 | Nov 27, 2023 | none ahead |
- Named in Sino Biopharmaceutical’s own pipeline as
TQH2929
, phase 2, as of Nov 16, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 27, 2023First study: phase 1 study in PsoriasisFirst studyNCT06156280 · 40 enrolled · China
- May 23, 2024Phase 1 study in PsoriasisNCT06433531 · 9 enrolled · China
- Dec 15, 2025Phase 2 study in PsoriasisPhase 2 reachedNCT07314060 · 36 enrolled · China
TargetBeta
“IL-36R抑制剂”the company's pipeline, read by Claude · source
Other programs on IL36R
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| SHR-1139 | Jiangsu HengRui Medicine | phase 2 | 8 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07314060Psoriasis · China | 2 | Terminated | Jul 30, 2026 | 36 |
| NCT06433531Psoriasis · China | 1 | Active, not recruiting | Jul 8, 2025 | 9 |
| NCT06156280Psoriasis · China | 1 | Completed | Aug 2, 2024 | 40 |
How it is read
Names in the registry
- “TQH2929 Injections”, 1 entry
- “TQH2929 Injection”, 1 entry
- “TQH2929 injection”, 1 entry
Codes read as this program: TQH2929.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.